NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — Daxor society (Nasdaq: DXR), the world leader in blood volume measurement technology, today announced that President and Chief Executive Officer Michael Feldschuh will present at the HC Wainwright Global Life Investment Hybrid Conference to be held from March 23 to May 26and at the Fontainebleau Hotel Miami Beach, Miami FL.
Mr. Feldschuh will present on May 25, 2022 at 4:30 p.m. ET and report on the company’s many accomplishments in the areas of financial performance, product commercialization, U.S. Department of Defense contracts, grant funding through the National Institute of Health, development of new technologies and new prospective medical trials for the use of Daxor’s BVA-100® blood test in the management of intensive care, COVID-19 and heart failure with leading institutions. Mr. Feldschuh will also be available for one-on-one meetings on site and meeting requests can be made once registered.
Event: HC Wainwright Global Investment Conference
Date: May 23-26and
Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing firstname.lastname@example.org.
On Daxor society
Daxor society (Nasdaq: DXR), is the world leader in blood volume measurement technology focused on innovation in blood volume testing. We have developed and marketed the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, and objective quantification of blood volume status and composition against patient-specific standards. More than 60,000 tests have been performed at major hospitals across the United States, improving hospital performance measures across a wide range of surgical and medical conditions, including dramatically reducing heart failure mortality and readmissions and intensive care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with NIH support and is developing analyzers under contract to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management through blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the impact of the hiring of sales personnel and the expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this release, including, without limitation, the risks associated with our post-marketing clinical data collection activities, the benefits of our products for patients, our expectations of product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection , FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other additional risks and uncertainties described in our SEC filings. Forward-looking statements speak only as of the date they are made. Daxor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact with Investor Relations:
Senior Managing Partner, CORE IR